MARC Record from marc_columbia

LEADER: 02335cam a22004934a 4500
001 7719312
005 20221201022728.0
008 090507s2009 enka b 001 0 eng
010 $a 2009019338
015 $aGBA951609$2bnb
016 7 $a101504356$2DNLM
016 7 $a015265607$2Uk
019 $a144227739
020 $a9780470060858 (cloth)
020 $a0470060859 (cloth)
029 1 $aNLM$b101504356
029 1 $aNLGGC$b320187411
035 $a(OCoLC)ocn321009115
035 $a(OCoLC)321009115$z(OCoLC)144227739
035 $a(NNC)7719312
035 $a7719312
040 $aDNLM/DLC$cDLC$dBTCTA$dBAKER$dNLM$dYDXCP$dBWKUK$dUKM
042 $apcc
050 00 $aRM301.27$b.S25 2009
060 00 $a2009 J-911
060 10 $aQV 771$bS163b 2009
082 00 $a615/.1901$222
100 1 $aMussen, Filip.$0http://id.loc.gov/authorities/names/n2009181964
245 10 $aBenefit-risk appraisal of medicines :$ba systematic approach to decision-making /$cFilip Mussen, Sam Salek, Stuart Walker.
260 $aChichester, UK ;$aHoboken, NJ :$bWiley-Blackwell,$c2009.
300 $ax, 294 pages :$billustrations ;$c25 cm
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
504 $aIncludes bibliographical references and index.
505 0 $aConcept and scope of benefit-risk evaluation of medicines -- Criteria for a benefit-risk model : a conceptual framework -- Review of the current benefit-risk assessment models -- Defining a systematic approach to decision making -- Development and application of a benefit-risk assessment model based on multi-criteria decision analysis -- A future framework for benefit-risk appraisal of medicines.
650 0 $aDrugs$xTesting.$0http://id.loc.gov/authorities/subjects/sh85039755
650 0 $aPharmaceutical policy$xDecision making.
650 12 $aDrug Evaluation$xstandards.$0https://id.nlm.nih.gov/mesh/D004341Q000592
650 22 $aDecision Support Techniques.$0https://id.nlm.nih.gov/mesh/D003661
650 22 $aModels, Theoretical.$0https://id.nlm.nih.gov/mesh/D008962
650 22 $aRisk Assessment.$0https://id.nlm.nih.gov/mesh/D018570
700 1 $aSalek, Sam.$0http://id.loc.gov/authorities/names/n97803241
700 1 $aWalker, Stuart R.,$d1944-$0http://id.loc.gov/authorities/names/n84039094
852 00 $boff,hsl$hRM301.27$i.S25 2009